A Phase 3 Trial of Brepocitinib in Dermatomyositis

28 Mar 20264 min read0 viewsJournal Feed

GIST

New England Journal of Medicine published a clinical update in Research Highlights on 28 Mar 2026. The item focuses on A Phase 3 Trial of Brepocitinib in Dermatomyositis. Review the original article for the full source wording and details.

Clinical Editorial

Summary

New England Journal of Medicine published a clinical update in Research Highlights on 28 Mar 2026.

The item focuses on A Phase 3 Trial of Brepocitinib in Dermatomyositis.

Review the original article for the full source wording and details.

Source Reference

Read the full original publication from the source journal or publisher link below.

Open Original Source More Feed Items

Related by Condition/Drug

PLOS ONERelated by Specialty

Cyberattacks in supply chains: A multi-case study

Research Highlights • 22 May 2026

PLOS ONERelated by Specialty

Timely Integration of specialist palliative care into oncology care for patients receiving radiotherapy for bone metastases: A study procotol for the TIPZO-RT Randomized Controlled Trial

Research Highlights • 22 May 2026

PLOS MedRelated by Specialty

Differences in tuberculosis prevalence by sex in low- and middle-income countries over 1993–2025: A systematic review and meta-analysis

Research Highlights • 22 May 2026

Med News TodayRelated by Specialty

Migraine with aura linked to higher stroke risk in older adults

Research Highlights • 23 May 2026

KFF HealthRelated by Specialty

Trump Bought Stock in Eli Lilly as His Policies Gave the Drugmaker a Big Boost, Documents Show

Research Highlights • 22 May 2026

Endocrine NewsRelated by Specialty

Pharma Friday – May 22, 2026

Research Highlights • 22 May 2026

Feed Metadata

Source

New England Journal of Medicine